Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is focused on assessing gastrointestinal-level improvements by which green tea limits metabolic endotoxemia. It is completed in two phases. Phase I consists of a pharmacokinetic study to examine the bioavailability of green tea catechins among lean and obese persons who consumed a single dose of a green tea extract (GTE)-containing confection. These persons will then complete phase 2, which consists of a parallel design randomized controlled in which lean and obese persons will consume placebo or GTE confections.
It is expected that catechin-rich green tea will improve gut barrier function to prevent endotoxin translocation and associated low-grade inflammation. Outcomes will therefore support dietary recommendations for green tea to alleviate obesity-related inflammatory responses. Specifically, the study is expected to demonstrate that a green tea confection snack food can attenuate metabolic endotoxemia in association with restoring gastrointestinal health.
Obesity is a major public health concern in the United States, with over two-thirds of the adult population classified as overweight or obese. Obesity is characterized by low-grade chronic inflammation that, in part, is mediated by metabolic endotoxemia. Metabolic endotoxemia describes increased circulating levels of gut-derived endotoxin (a bacterial product derived from Gram-negative bacteria in the intestines) that results from gut barrier dysfunction, a phenomenon that is common in obesity. Studies in rodents models have shown that dietary supplementation with green tea extract (GTE) reduces metabolic endotoxemia in association with improved gut health. This clinical trial will therefore investigate the extent to which a green tea confection snack food can alleviate metabolic endotoxemia and restore gut health in obese humans. It is hypothesized that 4-week daily ingestion of a green tea extract (GTE)-rich confection will limit metabolic endotoxemia by decreasing gut barrier permeability. This study will address the following objectives: 1) define alterations in catechin pharmacokinetics in obese compared with healthy adults, 2) demonstrate improvements in gut barrier function by GTE, and 3) demonstrate GTE-mediated amelioration of microbial dysbiosis.
To test the hypothesis, all participants will initially complete a 12-h pharmacokinetics study to define the influence of obesity on catechin bioavailability and metabolism. They will then be randomized to complete a double-blind, randomized, placebo-controlled trial where they will receive a GTE-rich or placebo confection for 4 weeks. Prior to and upon completing the intervention, participants will undergo a gut permeability test, fecal samples will be collected for microbiota composition analysis, and blood samples will be collected to assess endotoxin and inflammatory biomarkers. Upon successfully completing this study, it is anticipated that chronic consumption of a green tea confection will be demonstrated to be an effective dietary strategy to reduce metabolic endotoxemia and improve gut health.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Confection | Placebo Comparator | Confection without green tea extract consumed daily for 4 weeks |
|
| Green Tea Extract-Confection | Experimental | Confection with green tea extract consumed daily for 4 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Green Tea Extract | Other | Confections containing green tea extract that will be ingested daily for 4 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Endotoxin | Serum endotoxin concentration | Week 0 - Fasting |
| Endotoxin | Serum endotoxin concentration | Week 2 - Fasting |
| Endotoxin | Serum endotoxin concentration | Week 4 - Fasting |
| Measure | Description | Time Frame |
|---|---|---|
| Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Week 0 - 0-5 hours |
| Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard Bruno, PhD, RD | Ohio State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ohio State University | Columbus | Ohio | 43210 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28038359 | Background | Li J, Sapper TN, Mah E, Moller MV, Kim JB, Chitchumroonchokchai C, McDonald JD, Bruno RS. Green tea extract treatment reduces NFkappaB activation in mice with diet-induced nonalcoholic steatohepatitis by lowering TNFR1 and TLR4 expression and ligand availability. J Nutr Biochem. 2017 Mar;41:34-41. doi: 10.1016/j.jnutbio.2016.12.007. Epub 2016 Dec 21. | |
| 29190550 |
Not provided
Not provided
Data will be published as aggregate only. Data sharing may be possible pending institutional agreements.
Not provided
Not provided
Not provided
Not provided
In Phase 1, participants were stratified by phenotype (lean vs. obese) and received a single dose of a green tea extract (GTE)-enriched confection. This phase was conducted to evaluate catechin bioavailability. All participants consumed the same GTE confection. After a washout period, participants were randomized in Phase 2 to receive either a GTE or placebo confection daily for 4 weeks in a double-blind trial.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lean - Placebo | Confection without green tea extract consumed daily for 4 weeks Placebo: Confections containing no green tea extract that will be ingested daily for 4 weeks |
| FG001 | Lean - GTE | Confection with green tea extract consumed daily for 4 weeks Green Tea Extract: Confections containing green tea extract that will be ingested daily for 4 weeks |
| FG002 | Obese - Placebo | Confection without green tea extract consumed daily for 4 weeks Placebo: Confections containing no green tea extract that will be ingested daily for 4 weeks |
| FG003 | Obese - GTE | Confection with green tea extract consumed daily for 4 weeks Green Tea Extract: Confections containing green tea extract that will be ingested daily for 4 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic Study |
| |||||||||||||
| Randomized Controlled Trial |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo Confection | Confection without green tea extract consumed daily for 4 weeks Placebo: Confections containing no green tea extract that will be ingested daily for 4 weeks |
| BG001 | Green Tea Extract-Confection |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Endotoxin | Serum endotoxin concentration | Posted | Mean | Standard Deviation | EU/mL | Week 0 - Fasting |
|
1 month
Consumption of the formulated green tea extract did not put any of the participants at risk for serious adverse events, not did it put any participants at risk for all-cause omrtality.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Lean - Placebo | Lean Participants consumed a placebo confection for 1-month | 0 |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Richard Bruno | The Ohio State University | 614-292-5522 | bruno.27@osu.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 22, 2017 | Jan 27, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D019446 | Endotoxemia |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013662 | Tea |
| ID | Term |
|---|---|
| D028321 | Plant Preparations |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D001628 | Beverages |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Confections containing no green tea extract that will be ingested daily for 4 weeks |
|
| Week 0 - 6-24 hours |
| Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Week 4 - 0-5 hours |
| Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Week 4 - 6-24 hours |
| Gut Permeability - Sucralose to Erythritol Ratio | Urinary Sucralose/Erythritol Ratio (mg/mg) | Week 0 - 6-24 hours |
| Gut Permeability - Sucralose to Erythritol Ratio | Urinary Sucralose/Erythritol Ratio (mg/mg) | Week 0 - 0-24 hours |
| Urinary Sucralose/Erythritol Ratio (mg/mg) | Ratio of excretion of urinary sugars (Sucralose to Erythritol) | Week 4 - 6-24 hours |
| Gut Permeability - Sucralose to Erythritol Ratio | Urinary Sucralose/Erythritol Ratio (mg/mg) | Week 4 - 0-24 hours |
| Firmicutes to Bacteroidetes Ratio - Microbiota | Ratio of fecal relative Firmicutes (% abundance)/Bacteroidetes (% abundance) | Week 0 |
| Firmicutes to Bacteroidetes Ratio - Microbiota | Ratio of fecal relative Firmicutes (% abundance)/Bacteroidetes (% abundance) | Week 4 |
| Bioavailability - Epigallocatechin Gallate | Area under the curve (AUC) of plasma epigallocatechin calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epigallocatechin gallate is measured in umol/L over time (hours) resulting in the AUC. | Prior to intervention enrollment...0-12 hours post-ingestion of a green tea confection |
| Bioavailability - Epigallocatechin | Area under the curve (AUC) of plasma epigallocatechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epigallocatechin is measured in umol/L over time (hours) resulting in the AUC. | Prior to intervention enrollment...0-12 hours post-ingestion of a green tea confection |
| Bioavailability - Epicatechin Gallate | Area under the curve (AUC) of plasma epicatechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epicatechins is measured in umol/L over time (hours) resulting in the AUC. | Prior to the intervention enrollment...0-12 hours post-ingestion of a green tea confection |
| Bioavailability - Epicatechin | Area under the curve (AUC) of plasma epicatechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epicatechin is measured in umol/L over time (hours) resulting in the AUC. | Prior to intervention enrollment...0-12 hours post-ingestion of a green tea confection |
| Cmax of Epigallocatechin Gallate | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Cmax of Epigallocatechin | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Cmax of Epicatechin Gallate | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Cmax of Epicatechin | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Tmax of Epigallocatechin Gallate | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Tmax of Epigallocatechin | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Tmax of Epicatechin Gallate | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Tmax of Epicatechin | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
| Calprotectin | Fecal calprotectin concentration | Week 0 |
| Calprotectin | Fecal calprotectin concentration | Week 4 |
| Li J, Sasaki GY, Dey P, Chitchumroonchokchai C, Labyk AN, McDonald JD, Kim JB, Bruno RS. Green tea extract protects against hepatic NFkappaB activation along the gut-liver axis in diet-induced obese mice with nonalcoholic steatohepatitis by reducing endotoxin and TLR4/MyD88 signaling. J Nutr Biochem. 2018 Mar;53:58-65. doi: 10.1016/j.jnutbio.2017.10.016. Epub 2017 Nov 3. |
| COMPLETED |
|
| NOT COMPLETED |
|
Confection with green tea extract consumed daily for 4 weeks
Green Tea Extract: Confections containing green tea extract that will be ingested daily for 4 weeks
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Participants consumed gelatin extract with no green tea extract.
| OG003 | Obese - Placebo | Participants consumed gelatin extract with no green tea extract. |
|
|
| Primary | Endotoxin | Serum endotoxin concentration | Posted | Mean | Standard Deviation | EU/mL | Week 2 - Fasting |
|
|
|
| Primary | Endotoxin | Serum endotoxin concentration | Posted | Mean | Standard Deviation | EU/mL | Week 4 - Fasting |
|
|
|
| Secondary | Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Ratio | Week 0 - 0-5 hours |
|
|
|
| Secondary | Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Urinary Lactulose/Mannitol Ratio (mg/mg) | Week 0 - 6-24 hours |
|
|
|
| Secondary | Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Urinary Lactulose/Mannitol Ratio (mg/mg) | Week 4 - 0-5 hours |
|
|
|
| Secondary | Gut Permeability - Lactulose to Mannitol Ratio | Urinary Lactulose/Mannitol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Urinary Lactulose/Mannitol Ratio (mg/mg) | Week 4 - 6-24 hours |
|
|
|
| Secondary | Gut Permeability - Sucralose to Erythritol Ratio | Urinary Sucralose/Erythritol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Urinary Sucralose/Erythritol (mg/mg) | Week 0 - 6-24 hours |
|
|
|
| Secondary | Gut Permeability - Sucralose to Erythritol Ratio | Urinary Sucralose/Erythritol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Urinary Sucralose/Erythritol (mg/m | Week 0 - 0-24 hours |
|
|
|
| Secondary | Urinary Sucralose/Erythritol Ratio (mg/mg) | Ratio of excretion of urinary sugars (Sucralose to Erythritol) | Posted | Mean | Standard Deviation | Urinary Sucralose/Erythritol (mg/m | Week 4 - 6-24 hours |
|
|
|
| Secondary | Gut Permeability - Sucralose to Erythritol Ratio | Urinary Sucralose/Erythritol Ratio (mg/mg) | Posted | Mean | Standard Deviation | Urinary Sucralose/Erythritol (mg/m | Week 4 - 0-24 hours |
|
|
|
| Secondary | Firmicutes to Bacteroidetes Ratio - Microbiota | Ratio of fecal relative Firmicutes (% abundance)/Bacteroidetes (% abundance) | Posted | Mean | Standard Deviation | % of abundance | Week 0 |
|
|
|
| Secondary | Firmicutes to Bacteroidetes Ratio - Microbiota | Ratio of fecal relative Firmicutes (% abundance)/Bacteroidetes (% abundance) | Posted | Mean | Standard Deviation | ratio | Week 4 |
|
|
|
| Secondary | Bioavailability - Epigallocatechin Gallate | Area under the curve (AUC) of plasma epigallocatechin calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epigallocatechin gallate is measured in umol/L over time (hours) resulting in the AUC. | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L x h | Prior to intervention enrollment...0-12 hours post-ingestion of a green tea confection |
|
|
|
| Secondary | Bioavailability - Epigallocatechin | Area under the curve (AUC) of plasma epigallocatechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epigallocatechin is measured in umol/L over time (hours) resulting in the AUC. | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L x h | Prior to intervention enrollment...0-12 hours post-ingestion of a green tea confection |
|
|
|
| Secondary | Bioavailability - Epicatechin Gallate | Area under the curve (AUC) of plasma epicatechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epicatechins is measured in umol/L over time (hours) resulting in the AUC. | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L x h | Prior to the intervention enrollment...0-12 hours post-ingestion of a green tea confection |
|
|
|
| Secondary | Bioavailability - Epicatechin | Area under the curve (AUC) of plasma epicatechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection. Epicatechin is measured in umol/L over time (hours) resulting in the AUC. | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L x h | Prior to intervention enrollment...0-12 hours post-ingestion of a green tea confection |
|
|
|
| Secondary | Cmax of Epigallocatechin Gallate | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Cmax of Epigallocatechin | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Cmax of Epicatechin Gallate | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Cmax of Epicatechin | Maximum plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | umol/L | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Tmax of Epigallocatechin Gallate | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | h | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Tmax of Epigallocatechin | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | h | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Tmax of Epicatechin Gallate | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | h | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Tmax of Epicatechin | Time to maximal plasma concentration of catechins calculated from blood collected at 0, 0.25, 0.5, 1, 2, 3, 5, 8, 10, 12 hours post-ingestion of green tea confection | A pharmacokinetics study was completed regarding catechin bioavailability in all participants prior to the intervention randomization of treatment (GTE/Placebo). During this phase, all lean and obese participants of both groups consumed green tea extract containing confection. Bioavailability measures were then performed. | Posted | Mean | Standard Error | h | Prior to intervention enrollment...0-12 hours post-ingestion of green tea confection |
|
|
|
| Secondary | Calprotectin | Fecal calprotectin concentration | Posted | Mean | Standard Deviation | ug/g | Week 0 |
|
|
|
| Secondary | Calprotectin | Fecal calprotectin concentration | Posted | Mean | Standard Deviation | ug/g | Week 4 |
|
|
|
| 10 |
| 0 |
| 10 |
| 0 |
| 10 |
| EG001 | Obese - Placebo | Obese Participants consumed a placebo confection for 1-month | 0 | 9 | 0 | 9 | 0 | 9 |
| EG002 | Lean - GTE | Lean Participants consumed green tea extract containing confection (50 g 114 confection containing 0.5 g GTE) for 1-month | 0 | 10 | 0 | 10 | 0 | 10 |
| EG003 | Obese - GTE | Obese Participants consumed green tea extract containing confection (50 g 114 confection containing 0.5 g GTE) for 1-month | 0 | 10 | 0 | 10 | 0 | 10 |
Not provided
Not provided
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D016470 | Bacteremia |
| D018805 | Sepsis |
| D007239 | Infections |
| D014115 | Toxemia |
| D018746 | Systemic Inflammatory Response Syndrome |
| D010335 | Pathologic Processes |
| D000066888 |
| Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |